Compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer’s disease can cause gastrointestinal and other side effects. Thanks to the discovery of a truly selective agonist that targets only the M1 receptor, this may change.